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Abstract 
Background : To compare the clinical efficacy of 
intravenous (I/V) Ceftriaxone with oral 
Azithromycin in 2-12 year old children diagnosed 
with enteric fever. 
Methods: In this comparative study children with 
the history of fever for >4 days and at least two  out 
of these findings, i.e., toxic physical appearance, 
abdominal pain, coated tongue, hepatomegaly, 
splenomegaly were divided into two equal groups. 
Patients in Group A were given Azithromycin 20 mg 
/ kg/ day as a single oral dose whereas patients in 
Group B were given Ceftriaxone 100 mg/kg/day as a 
single I/V injection for 07 days. Before initiation of 
therapy samples for Typhidot and Widal test were 
collected and only those testing positive were 
included. 
Results: There were 42 (93.3%) and 40 (88.9%) 
patients in both the groups respectively who were 
clinically cured. No significant difference was found 
between these two groups (p-value 0.459). 
Conclusion: There was no difference in the 
clinical efficacy between Ceftriaxone and 
Azithromycin for the treatment of typhoid fever in 
children.  
Key Words: Typhoid fever, Salmonella Typhi, 
Antibacterial agents, Febrile illness 
 
Introduction 
Enteric fever is a fatal multi-systemic illness caused by 
a gram-negative bacterium Salmonella typhi and 
Paratyphi. It is one of the major public health 
burden.1,2 The global estimate of incidence of enteric 
fever is 26.9 million cases annually, out of which 1 % 
result in death.3 The highest incidence is in South 
Central and South East Asia (100/100,000 cases/year) 
with the highest burden in children aged 2 – 15 years.  
Annual typhoid rates in recent studies from India, 
Pakistan & Indonesia range from 149 to 573 cases per 
100,000 children.8 Poor sanitary conditions and 
overcrowding favor its growth. Its route of 
transmission is faeco-oral. 4-7 
Its classical presentation is high grade fever, 
headache,malaise, anorexia, abdominal 
pain,constipation or diarrhea and maculopapular rash 
(rose spots) on the trunk lasting for 2-5 days in 25% of 
cases.9Serious complications may develop inup to 10% 
cases during third week of illness such as intestinal 
hemorrhages and perforation, meningitis, pneumonia, 
myocarditis,DIC,thrombocytopenia,encephalomyelitis, 
psychosis, hepatitis, haemolytic uremic syndrome and 
Guillain-Barre syndrome.9,10 Mortality rate of enteric 
fever is <1% but it is high if treatment is delayed.11 
Therefore antimicrobials have the prime role in its 
management. 
Because of the irrational use of antibiotics, over the 
counter medicines and the resultant emergence of 
resistance, its treatment is becoming difficult.10 
Previously Chloramphenicol,Ampicillin and Co-
trimoxazole were used for its treatment. In 1980 
emergence of resistance to these first line drugs 
[defined as multidrug resistance (MDR)] limited their 
use. 9,12,13  MDR strains were first reported from Asia 
and Middle East and later from all over the world.10 
Nowadays, widespread use of Fluroquinolones led to 
the development of quinolones resistant strains.12 
Recent studies done in India showed increasing 
resistance to Ceftriaxone as well.14,15 For this reason, it 
is necessary to search for new antibiotic options for 
enteric fever. 
The recommended first line treatment for Enteric fever 
is Third generation  Cephalosporins, for 
uncomplicated cases oral Cefixime or Cefpodoxime 
and for complicated cases I/V Ceftriaxone, 
Cefotaxime, or Cefoperazone.9 Recent studies showed 
that for Ceftriaxone resistant strains, Azithromycin has 
good efficacy with safety.12,16,17It is recommended in a 
dose of 20 mg/kg/day (maximum -1000 mg/day) for 
7 days.12,17 Various studies have shown clinical cure 
Journal of Rawalpindi Medical College (JRMC); 2019;23(2): 64-67 
 65 
of94%-96% for Azithromycin compared with 27% for 
Ceftriaxone.  18,19 
Prompt treatment of Enteric fever drastically reduces 
the complications and mortality. We use both 
Azithromycin and Ceftriaxone for treatment of 
typhoid fever in our population.  
 
Patients and Methods 
This randomized controlled trial was conducted in 
Department of Paediatrics, Railway Hospital and 
Islamic International Medical College, from January to 
July 2016. Sample size was approximately equal to 45 
patients in each group. Group A comprised patients on 
Oral Azithromycin and Group B comprised patients 
on intravenous Ceftriaxone. Inclusion criteria was 
children between 2 and 12 years of age of either sex 
with enteric fever.  Exclusion criteria were  children 
who have taken treatment for their illness, who had 
allergy to Ceftriaxone or Azithromycin (other 
macrolides), who were unable to swallow oral 
medications and with complications like 
gastrointestinal haemorrhage; intestinal perforation or 
shock.Typhoid Fever was  defined as temperature 
>38.5 C and a history of fever for at least 04 days plus 
at least two of the following criteria: toxic physical 
appearance (like pallor, lethargy, irritibility, (>16 beats 
/ min > 100 beats /min) tachypnea, abdominal pain, 
coated tongue, hepatomegaly (on clinical 
examination), splenomegaly (on clinical examination) 
with a positive Widal test (TO titer equal or > 160 with 
TO > TH) or a positive Typhidot test. Clinical Cure 
(Efficacy) was defined as clinical improvement and 
resolution of all symptoms by the end of seven days of 
therapy.Patients enrolled in the study were 
hospitalized for the entire treatment period and 3 days 
after completion of therapy.Group A patients were 
given Azithromycin 20mg/kg/day as single oral dose 
for 07 days. Group B patients were given Ceftriaxone 
100mg/kg/day as single I/V injection for 07 days. 
During hospital stay, vital signs were monitored 8 
hourly, and patients were examined daily to assess the 
effectiveness of treatment. Chi-square test was used to 
compare efficacy in both the groups. P value <0.05 was 
significant. Effect modifiers like age and gender were 
controlled by stratification. For Post stratification Chi-
square test was applied and a value < 0.05 was taken 
as level of significance.                                                
 
Results 
  Mean age (years) in the study was 6.97+3.01 with 
ranges from 02 to 12 years. There were 47 (52.2%) male 
and 43 (47.8%) female patients. Majority (91.1%) were 
cured from symptoms of typhoid by the end of seven 
days of therapy(Table 1).Majority (93.3) were 
symptom free at the end of 07 days who received 
Azithromycin whereas 40 (88.9) patients were cured 
with Ceftriaxone(p-value 0.459;Table 2). There  were 
22 (91.7) and 19 (82.6) male patients in both the groups 
respectively who were clinically cured which was 
statistically not significant (p-value 0.352). Similarly, 
efficacy in female patients in both the groups was 
statistically not significant (p-value 0.973;Table 3). In 
children of 2-6 years azithromycin was effective in 
92% cases while ceftriaxone showed 95% efficacy as 
compared to children of 7-12 years age in whom 
azithromycin was more efficacious (95%) than 
ceftriaxone(84%) (Table 4). 
 
Table 1: Frequency and percentage of Clinical 
Cure (efficacy) 
 Frequency Percentage 
 
Achieved 82 91.1 
Not achieved 08 8.9 
Total 90 100.0 
Table 2:Comparison of Clinical Cure (efficacy) 
in both the groups 
Clinical cure 
(efficacy) 
Azithromycin 
Group (Oral) 
Ceftriaxone 
Group (I.V) 
p-value 
Achieved  
Number(%) 
42(93.3) 40(88.9) 0.459 
Not achieved 
Number (%) 
3(6.7) 5(11.1)  
Table 3: Effect modifier like gender 
stratification with efficacy in both the groups 
Gender Clinical Cure 
(Efficacy) 
Azithromycin 
Group (Oral) 
Cefitriaxone 
Group (I.V) 
p-value 
Male Achieved 
Number (%) 
22(91.7) 19(82.6) 0.352 
Not achieved 
Number (%) 
2(8.3) 4(17.4) 
Female Achieved 
Number(%) 
20(95.2) 21(95.5) 0.973 
Not achieved 
Number (%) 
1(4.8) 1(4.5) 
Table  4 :Effect modifier like Age stratification 
with Efficacy in both the groups 
Age Group Clinical 
Cure (efficacy) 
Azithromycin 
Group (Oral) 
Cefitraxone 
Group (I.V) 
p-
value 
2 – 6 
years 
Achieved 
Number (%) 
23(92.0) 19(95.0) 0.688 
Not achieved 
Number (%) 
2(8.0) 1(5.0) 
7 – 12 
years 
Achieved 
Number(%) 
19(95.0) 21(84.0) 0.243 
Not achieved 
Number (%) 
1(5.0) 4(16.0) 
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Discussion 
Enteric fever is a major health problem in developing 
countries like Pakistan but now it’s becoming a global 
health concern because of the emergence of resistant 
strains of Salmonella typhi and paratyphi. Resistance 
has been documented with most of the first line drugs 
like cephalosporins and quinolones.20 Few studies 
reported that Azithromycin is highly effective in 
uncomplicated Enteric fever in adults and children.21 
In our study, mean age (years) in the study was 
6.97+3.01 with ranges from 02 to 12 years. In a study 
conducted by Hussain et al, mean age in years was 
6.09+3.09 and in the study conducted by Aggarwal et 
al it was 7.5 years.22,23A study in 2012 observed that 
the frequency and percentage of male patients was 
33(55) and female patients was 27(45.0). 21 The study 
conducted in India observed 93.5% males.23 In our 
study, there were 47 (52.2) male and 43 (47.8) female 
patients. In our study, out of 90 patients, there were 82 
(91.1%) patients who were cured by the end of seven 
days of therapy. Whereas in a study conducted in 
2012, there were 49(98%) patients who had a complete 
cure. 21 
In present study while comparing clinical cure 
(efficacy), there were 93.3% patients who were cured 
by Azithromycin whereas 88.9% patients were cured 
by Ceftriaxone. While in a study conducted by 
Machakanuret al , the cure rateswere 96% in patients 
treated with Azithromycin compared with 27% of 
patients who received I/V Ceftriaxone. 24 A study, 
conducted in 2012, showed Azithromycin to be 
effective in 94.6% patients.22A non-comparative study 
conducted in India revealed that azithromycin was 
effective in 90% of the patients.23 Two more studies 
revealed the efficacy of Azithromycin to be 82 & 
92%.25,26 
The sensitivity to ceftriaxone was 100 % in 2 studies 
conducted in India in 2000  and 2005  while we found 
the sensitivity to be 88.9%.27,28 A meta-analysis of 20 
prospective clinical trials revealed Azithromycin to be 
a better choice as compared to other antibiotics being 
commonly used while our study showed no difference 
of efficacy between Ceftriaxone and Azithromycin. 29 
Our results were closer to another study conducted in 
Dhaka in 2009 which showed Azithromycin 
effectiveness to be 94% while ceftriaxone was 97.9%.30 
Both studies showed Azithromycin and Ceftriaxone to 
be highly effective in uncomplicated typhoid fever. 
 
Conclusion 
There is no difference of clinical efficacy among 
Ceftriaxone and Azithromycin for the treatment of 
uncomplicated typhoid fever in children.  
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